Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
Authors:
- 9 February 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 10 (3) , 207-215
Abstract
Multiple myeloma (MM) is a rare hematologic disease of antibody-secreting plasma cells. Our understanding of the pathogenesis of this malignancy has improved greatly, and at the same time, we have access to new and more effective treatments options. Over the last 5 years, a spectrum of novel therapies with different mechanisms of action, including third-generation immunomodulatory drugs (pomalidomide), second generation proteasome inhibitors (carfilzomib and ixazomib), a histone deacetylase inhibitor (panobinostat) and monoclonal antibodies (mAbs) (elotuzumab and daratumumab) has transformed our approach to the treatment of patients with relapsed/refractory MM (RRMM). Areas covered: In this review, we will summarize the characteristics of the new drugs used in RRMM with a specific focus on recent phase 3 trials of triplet combinations in this setting and the rationale behind the selection of one regimen over another. Expert commentary: Several recent phase III trials conducted with patients with RRMM have demonstrated that triplet combinations are associated with a deeper response and an increased duration of response compared to standard treatments. These effective regimens may control the emerging drug resistant clones leading to progression. However, they have distinct toxicity profiles, which need to be taken into account by patients and care givers. The landscape of RRMM is changing rapidly, and new standards of care are proposed.Keywords
This publication has 57 references indexed in Scilit:
- Multiple Myeloma: From Front-Line to Relapsed TherapiesAmerican Society of Clinical Oncology Educational Book, 2015
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Epidemiology of Multiple Myeloma2011
- Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE projectBlood, 2010
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia, 2009
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004